JNJ-79635322
Sponsors
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale, Universitaetsklinikum Heidelberg AöR, Janssen Cilag International, Janssen Research & Development, LLC, University of Heidelberg Medical Center
Conditions
Immunoglobulin Light-chain AmyloidosisMultiple MyelomaNewly Diagnosed Multiple MyelomaNewly Diagnosed Multiple Myeloma in patients eligible for stem cell transplantationPreviously Treated Amyloid Light-chain (AL) AmyloidosisRelapsed or Refractory
Multiple Myeloma (RRMM)Relapsed or Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RecruitingNCT05652335
Start: 2022-11-22End: 2030-11-15Target: 180Updated: 2026-09-28
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
RecruitingNCT06768489
Start: 2024-12-04End: 2029-06-29Target: 276Updated: 2026-09-25
Phase 2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
RecruitingNCT05695508
Start: 2022-12-01End: 2029-09-15Target: 160Updated: 2025-12-24
A Phase 2, Multi-cohort Study Applying Innovative MRD Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma - TAURUS
RecruitingCTIS2023-505221-14-00
Start: 2023-12-04Target: 237Updated: 2026-01-26
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma
RecruitingCTIS2024-517382-17-00
Start: 2022-11-30Target: 130Updated: 2025-08-19
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruitingNCT07266441
Start: 2026-02-08End: 2028-12-12Updated: 2026-09-25
A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Not yet recruitingCTIS2025-521976-80-00
Target: 28Updated: 2026-05-14
Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of
Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in
Participants With Relapsed/Refractory Multiple Myeloma
Not yet recruitingCTIS2025-524793-42-00
Target: 81Updated: 2026-08-26
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingNCT07258511
Start: 2026-02-04End: 2031-09-30Target: 400Updated: 2026-09-25
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingNCT07518186
Start: 2026-05-31End: 2032-12-08Target: 700Updated: 2026-09-25
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Not yet recruitingCTIS2025-522007-18-00
Target: 42Updated: 2026-05-19
"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with
Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an
Anti-CD38 Antibody and Lenalidomide"
Not yet recruitingCTIS2025-523815-12-00
Target: 181Updated: 2026-07-03
A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
Not yet recruitingCTIS2026-526654-14-01
Target: 221Updated: 2026-09-18